GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » Enterprise Value

Mercury Biopharmaceutical (ROCO:6932) Enterprise Value : NT$6,264.67 Mil (As of Jun. 19, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mercury Biopharmaceutical Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mercury Biopharmaceutical's Enterprise Value is NT$6,264.67 Mil. Mercury Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-43.11 Mil. Therefore, Mercury Biopharmaceutical's EV-to-EBIT ratio for today is -145.34.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Mercury Biopharmaceutical's Enterprise Value is NT$6,264.67 Mil. Mercury Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-39.03 Mil. Therefore, Mercury Biopharmaceutical's EV-to-EBITDA ratio for today is -160.49.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Mercury Biopharmaceutical's Enterprise Value is NT$6,264.67 Mil. Mercury Biopharmaceutical's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00 Mil. Therefore, Mercury Biopharmaceutical's EV-to-Revenue ratio for today is .


Mercury Biopharmaceutical Enterprise Value Historical Data

The historical data trend for Mercury Biopharmaceutical's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Biopharmaceutical Enterprise Value Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - - 3,937.40 7,408.57

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial - - 3,937.40 10,563.72 7,408.57

Competitive Comparison of Mercury Biopharmaceutical's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mercury Biopharmaceutical's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Mercury Biopharmaceutical's Enterprise Value falls into.



Mercury Biopharmaceutical Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Mercury Biopharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Mercury Biopharmaceutical's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mercury Biopharmaceutical  (ROCO:6932) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Mercury Biopharmaceutical's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6264.673/-43.105
=-145.34

Mercury Biopharmaceutical's current Enterprise Value is NT$6,264.67 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-43.11 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Mercury Biopharmaceutical's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=6264.673/-39.034
=-160.49

Mercury Biopharmaceutical's current Enterprise Value is NT$6,264.67 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-39.03 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Mercury Biopharmaceutical's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6264.673/0
=

Mercury Biopharmaceutical's current Enterprise Value is NT$6,264.67 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Mercury Biopharmaceutical's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mercury Biopharmaceutical Enterprise Value Related Terms

Thank you for viewing the detailed overview of Mercury Biopharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Mercury Biopharmaceutical (ROCO:6932) Business Description

Traded in Other Exchanges
N/A
Address
No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.

Mercury Biopharmaceutical (ROCO:6932) Headlines

No Headlines